Cizzle Biotechnology is a spin-out from the University of York and is a biotechnology business focused on the early detection of Lung cancer via the development of an immunoassay test for the CIZ1B biomaker. Cizzle Biotechnology was initially funded by Yorkshire Cancer Research, White Rose Technology Seed Corn Fund, Finance Yorkshire Seedcorn LLP and Viking Members, who with management, invested in the project to support the development of a prototype blood test.
| Executive Chairman: |
Allan John Syms |
| Executive Director: |
Dawn Alison Coverley |
| Finance Director: |
Nigel Ronald Lee |
| Independent Non-Executive Director: |
John Treacy |
| Non-Executive Director: |
Edwin Matthew (Matt) Bower |
| Address: |
Level 19, The Shard, 32 London Bridge Street, London, United Kingdom |
| Phone: |
+44 (0)20 3934 6630 |
| Fax: |
|
| Website: |
http://www.cizzlebiotechnology.com |
| Email: |
|